PT3237406T - Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidino-2,4-diona como inibidores de adamts para o tratamento de osteoartrite - Google Patents
Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidino-2,4-diona como inibidores de adamts para o tratamento de osteoartriteInfo
- Publication number
- PT3237406T PT3237406T PT15813831T PT15813831T PT3237406T PT 3237406 T PT3237406 T PT 3237406T PT 15813831 T PT15813831 T PT 15813831T PT 15813831 T PT15813831 T PT 15813831T PT 3237406 T PT3237406 T PT 3237406T
- Authority
- PT
- Portugal
- Prior art keywords
- osteoartrite
- propil
- imidazolidine
- piperazin
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14307129 | 2014-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3237406T true PT3237406T (pt) | 2019-03-19 |
Family
ID=52345014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15813831T PT3237406T (pt) | 2014-12-22 | 2015-12-18 | Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidino-2,4-diona como inibidores de adamts para o tratamento de osteoartrite |
Country Status (50)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3501B1 (ar) * | 2014-12-22 | 2020-07-05 | Servier Lab | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) |
| GB201610056D0 (en) * | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| GB201610055D0 (en) * | 2016-06-09 | 2016-07-27 | Galapagos Nv And Laboratoires Servier Les | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis |
| CN107652277A (zh) * | 2017-08-09 | 2018-02-02 | 江苏工程职业技术学院 | 一种依帕列净的制备方法 |
| CN107540648A (zh) * | 2017-08-09 | 2018-01-05 | 江苏工程职业技术学院 | 一种达格列净的制备方法 |
| WO2021011720A2 (en) * | 2019-07-18 | 2021-01-21 | Avidence Therapeutics, Inc. | Anti-osteoarthritis compounds and related compositions and methods |
| WO2021158626A1 (en) * | 2020-02-04 | 2021-08-12 | Eternity Bioscience Inc. | Adamts inhibitors, preparation methods and medicinal uses thereof |
| WO2021204185A1 (zh) * | 2020-04-10 | 2021-10-14 | 深圳信立泰药业股份有限公司 | 一种苯并[d]氮杂卓类衍生物蛋白聚糖酶2抑制剂及其制备方法和医药用途 |
| CN113735825B (zh) * | 2020-05-27 | 2024-08-27 | 成都康弘药业集团股份有限公司 | 1,2,3,6-四氢吡啶类化合物及其制备方法和用途 |
| CN113754635B (zh) * | 2020-06-02 | 2024-06-21 | 成都康弘药业集团股份有限公司 | 稠环类化合物及其制备方法和用途 |
| WO2022007866A1 (zh) * | 2020-07-09 | 2022-01-13 | 深圳信立泰药业股份有限公司 | 并三环类衍生物、其制备方法及其在医药上的应用 |
| CN113943255B (zh) * | 2020-07-17 | 2024-08-06 | 深圳信立泰药业股份有限公司 | 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法 |
| CN116723840A (zh) * | 2020-12-15 | 2023-09-08 | 加拉帕戈斯股份有限公司 | (5s)-环丙基-5-[3-[(3s)-4-(3,5-二氟苯基)-3-甲基-哌嗪-1-基]-3-氧代-丙基]咪唑烷-2,4-二酮的固体形式 |
| EP4263530A1 (en) | 2020-12-15 | 2023-10-25 | Galapagos N.V. | Solid forms of (5s)-cyclopropyl-5-[3-[(3s)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione |
| CN117136051A (zh) * | 2021-04-02 | 2023-11-28 | 江苏恒瑞医药股份有限公司 | Adamts抑制剂的前药、其制备方法和医药用途 |
| CN117794900A (zh) * | 2021-08-03 | 2024-03-29 | 江苏恒瑞医药股份有限公司 | 抑制adamts-5和/或adamts-4功能的化合物的晶型及其制备方法和应用 |
| US20250313558A1 (en) | 2023-03-17 | 2025-10-09 | Cellus Inc. | Imidazolidine derivative or pharmaceutically acceptable salt thereof, and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4556670A (en) * | 1982-12-06 | 1985-12-03 | Pfizer Inc. | Spiro-3-hetero-azolones for treatment of diabetic complications |
| HU198212B (en) * | 1984-07-20 | 1989-08-28 | Pfizer | Process for production of spiro-imidasolones |
| US5043447A (en) * | 1987-04-24 | 1991-08-27 | Syntex Pharmaceuticals, Ltd. | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| GB0405101D0 (en) | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| US7504424B2 (en) * | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| PT2650310T (pt) | 2012-04-13 | 2016-09-01 | Rottapharm Biotech Srl | Anticorpo anti-adamts-5, derivados e utilizações dos mesmos |
| AR092971A1 (es) * | 2012-10-26 | 2015-05-06 | Lilly Co Eli | Inhibidores de agrecanasa |
| ES2627281T3 (es) | 2013-02-06 | 2017-07-27 | Merck Patent Gmbh | Derivados del ácido carboxílico sustituidos como agregados agrecanasa para el tratamiento de la artrosis |
| JO3501B1 (ar) | 2014-12-22 | 2020-07-05 | Servier Lab | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) |
-
2015
- 2015-11-19 JO JOP/2015/0284A patent/JO3501B1/ar active
- 2015-12-14 TW TW104141953A patent/TWI687414B/zh active
- 2015-12-18 DK DK15813831.3T patent/DK3237406T3/da active
- 2015-12-18 HU HUE15813831A patent/HUE042840T2/hu unknown
- 2015-12-18 EP EP15813831.3A patent/EP3237406B1/en active Active
- 2015-12-18 KR KR1020177020379A patent/KR102711990B1/ko active Active
- 2015-12-18 AU AU2015371400A patent/AU2015371400B2/en active Active
- 2015-12-18 SG SG11201705030SA patent/SG11201705030SA/en unknown
- 2015-12-18 LT LTEP15813831.3T patent/LT3237406T/lt unknown
- 2015-12-18 RS RS20190497A patent/RS58617B1/sr unknown
- 2015-12-18 CA CA2971110A patent/CA2971110C/en active Active
- 2015-12-18 RU RU2017126187A patent/RU2693459C2/ru active
- 2015-12-18 BR BR112017013258-3A patent/BR112017013258B1/pt active IP Right Grant
- 2015-12-18 PE PE2017001122A patent/PE20171099A1/es unknown
- 2015-12-18 NZ NZ732909A patent/NZ732909A/en unknown
- 2015-12-18 GE GEAP201514546A patent/GEP20197043B/en unknown
- 2015-12-18 UA UAA201707702A patent/UA122065C2/uk unknown
- 2015-12-18 AR ARP150104189A patent/AR103170A1/es active IP Right Grant
- 2015-12-18 CU CUP2017000085A patent/CU20170085A7/xx unknown
- 2015-12-18 PL PL15813831T patent/PL3237406T3/pl unknown
- 2015-12-18 US US15/538,393 patent/US9926281B2/en active Active
- 2015-12-18 JP JP2017551003A patent/JP6636539B2/ja active Active
- 2015-12-18 PT PT15813831T patent/PT3237406T/pt unknown
- 2015-12-18 WO PCT/EP2015/080430 patent/WO2016102347A1/en not_active Ceased
- 2015-12-18 MD MDE20170225T patent/MD3237406T2/ro unknown
- 2015-12-18 EP EP19154886.6A patent/EP3575294A1/en not_active Withdrawn
- 2015-12-18 ME MEP-2019-92A patent/ME03374B/me unknown
- 2015-12-18 TR TR2019/04158T patent/TR201904158T4/tr unknown
- 2015-12-18 HK HK18105455.7A patent/HK1245793B/en unknown
- 2015-12-18 ES ES15813831T patent/ES2724989T3/es active Active
- 2015-12-18 MX MX2017008048A patent/MX2017008048A/es active IP Right Grant
- 2015-12-18 MA MA41238A patent/MA41238B1/fr unknown
- 2015-12-18 TN TN2017000213A patent/TN2017000213A1/en unknown
- 2015-12-18 EA EA201791451A patent/EA030637B1/ru unknown
- 2015-12-18 CR CR20170248A patent/CR20170248A/es unknown
- 2015-12-18 HR HRP20190514TT patent/HRP20190514T1/hr unknown
- 2015-12-18 CN CN201580070274.0A patent/CN107108579B/zh active Active
- 2015-12-18 GE GEAP201914546A patent/GEAP201914546A/en unknown
- 2015-12-18 SI SI201530668T patent/SI3237406T1/sl unknown
- 2015-12-18 MY MYPI2017702301A patent/MY189764A/en unknown
- 2015-12-22 UY UY0001036470A patent/UY36470A/es not_active Application Discontinuation
-
2017
- 2017-05-24 GT GT201700107A patent/GT201700107A/es unknown
- 2017-06-07 ZA ZA2017/03905A patent/ZA201703905B/en unknown
- 2017-06-14 DO DO2017000139A patent/DOP2017000139A/es unknown
- 2017-06-15 SA SA517381743A patent/SA517381743B1/ar unknown
- 2017-06-18 IL IL252981A patent/IL252981B/en active IP Right Grant
- 2017-06-20 PH PH12017501160A patent/PH12017501160A1/en unknown
- 2017-06-21 NI NI201700081A patent/NI201700081A/es unknown
- 2017-06-21 CO CONC2017/0006174A patent/CO2017006174A2/es unknown
- 2017-06-21 CL CL2017001650A patent/CL2017001650A1/es unknown
- 2017-07-20 EC ECIEPI201746848A patent/ECSP17046848A/es unknown
-
2018
- 2018-02-14 US US15/896,779 patent/US10487060B2/en active Active
-
2019
- 2019-05-02 CY CY20191100464T patent/CY1121692T1/el unknown
- 2019-10-15 US US16/653,668 patent/US10941117B2/en active Active
- 2019-12-18 JP JP2019227801A patent/JP2020063278A/ja active Pending
-
2021
- 2021-01-05 US US17/141,902 patent/US11718588B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3237406T (pt) | Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidino-2,4-diona como inibidores de adamts para o tratamento de osteoartrite | |
| FR24C1016I1 (fr) | Inhibiteurs de ret | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| DK3157527T3 (da) | Ezh2-hæmmere til lymfombehandling | |
| ES2716415T3 (es) | Espirocicloheptanos como inhibidores de ROCK | |
| PT3580220T (pt) | Aminotriazolopiridinas como inibidores de quinase | |
| LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
| DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
| PT3209656T (pt) | Compostos de indol carboxamida úteis como inibidores de quinase | |
| IL250923A0 (en) | Novel compounds as rearranged during transfection (ret) inhibitors | |
| BR112017025542A2 (pt) | compostos de naftiridina como inibidores de quinase jak | |
| LT3190113T (lt) | Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai | |
| EP3247692A4 (en) | INHIBITORS OF TRKA KINASE | |
| ME03485B (me) | Derivati benzimidazola kao inhibitori bromodomena | |
| CL2016002638A1 (es) | Nuevos inhibidores de la nitrificación | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| IL261047A (en) | Taf1 inhibitors for the therapy of cancer | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| PT3083617T (pt) | Derivados de isocromeno como inibidores de fosfoinositídeo 3-quinase | |
| LT3288944T (lt) | Imidazopirazinonai, kaip pde1 inhibitoriai | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| HUE042064T2 (hu) | Pirrolidinon-származékok MetAP-2 inhibitorokként | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| IL246345A0 (en) | History of 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid as neprilysin inhibitors | |
| PT3552017T (pt) | Compostos úteis como inibidores de ripk1 |